According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
WASHINGTON -- Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and high-risk prostate cancer over standard lymphadenectomy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results